FINWIRES · TerminalLIVE
FINWIRES

$BNTX

29 stories mentioning BNTXUpdated 6d ago

Every FINWIRES story that references BNTX, newest first.

Asia Markets

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading

European equities traded in the US as American depositary receipts were tracking higher late Friday morning, rising 0.55% to 1,910.34 on the S&P Europe Select ADR Index, which is up about 0.4% for the week so far.From continental Europe, the gainers were led by software firm SAP (SAP) and semiconductor company Sequans Communications (SQNS), which rose 7% and 2.8%, respectively. They were followed by pharmaceutical firm Novo Nordisk (NVO) and lender Banco Santander (SAN), which advanced 2.5% and 2.4%, respectively.The decliners from continental Europe were led by telecommunications company Nokia (NOK) and biopharmaceutical company DBV Technologies (DBVT), which dropped 4.7% and 2.9% respectively. They were followed by internet ad firm Criteo (CRTO) and biotech company BioNTech (BNTX), which lost 2.1% and 1.3% respectively.The gainers from the UK were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and communications company WPP (WPP), which increased 3.7% and 2.3% respectively. They were followed by medical device maker Smith & Nephew (SNN) and educational publisher Pearson (PSO), which were up 1.7% and 1.6% respectively.The decliners from the UK and Ireland were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company Bicycle Therapeutics (BCYC), which fell 4.7% and 3% respectively. They were followed by biopharmaceutical company Akari Therapeutics (AKTX) and biotech firm Autolus Therapeutics (AUTL), which were down 2.5% and 2% respectively.

$AKTX$AUTL$BCYC$BNTX$CRTO$DBVT$NOK$NVO$PSO$SAN$SAP$SLN$SNN$SQNS$WPP
Wire

Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says

Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather than macroeconomic factors, Morgan Stanley said in a note Tuesday.As of July 6, the NYSE Arca Pharmaceutical Index has gained 11% and the Nasdaq Biotechnology Index has added 18%, compared with a 10% gain for the S&P 500 Index, with recent stock performance driven more by changes in valuation multiples than by earnings estimate revisions, the investment bank said.Morgan Stanley said its US Equity Strategy team expects the sector to benefit from broader market leadership. Biotech remains one of the most rate-sensitive sectors, and historically, the sector has delivered nearly 20% annualized returns during falling-rate environments, according to the note.In addition, merger and acquisition activity remains healthy, with several $5 billion to $10 billion deals recently announced, including AbbVie (ABBV) purchasing Apogee (APGE), and Vertex Pharmaceuticals (VRTX) buying Crinetics Pharmaceuticals (CRNX), the investment bank said.Morgan Stanley adjusted its price targets on Biogen (BIIB) to $222 from $224, Amgen (AMGN) to $333 from $340, Gilead Sciences (GILD) to $166 from $168, AbbVie to $279 from $278, Moderna (MRNA) to $39 from $33, BioNTech (BNTX) to $119 from $126, Regeneron Pharmaceuticals (REGN) to $730 from $788, Johnson & Johnson (JNJ) to $284 from $283, and Eli Lilly (LLY) to $1,347 from $1,344.Shares of Biogen, Amgen, Gilead, AbbVie, Moderna, BioNTech, Regeneron, Johnson & Johnson, and Eli Lilly were down 2%, 0.1%, 0.8%, 0.4%, 7%, 1.9%, 1.9%, 0.4%, and 0.5% respectively, in Wednesday trading.Price: $201.67, Change: $-4.03, Percent Change: -1.96%

$ABBV$AMGN$APGE$BIIB$BNTX$CRNX$GILD$JNJ$LLY$MRNA$REGN$VRTX
Asia Markets

European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading

European equities traded in the US as American depositary receipts were sharply higher late Thursday morning, advancing 2.21% to 1,927.62 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and biotech firm Evaxion (EVAX), which climbed 14% and 6.9% respectively. They were followed by biotech company BioNTech (BNTX) and biopharmaceutical company DBV Technologies (DBVT), which advanced 4.5% and 4.1% respectively.The only decliners from continental Europe were telecommunications company Nokia (NOK) and medical device maker EDAP (FOCL), which were down 1% and 0.8% respectively.The gainers from the UK were led by biopharmaceutical companies Akari Therapeutics (AKTX) and NuCana (NCNA), which rose 8.6% and 6.6% respectively. They were followed by biotech firm Autolus Therapeutics (AUTL) and pharmaceutical company Silence Therapeutics (SLN), which were up 4.8% and 3.7% respectively.The only decliners from the UK and Ireland were biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and Amarin (AMRN), which were off 1% and 0.3% respectively.

$AKTX$AMRN$AUTL$BDRX$BNTX$CLLS$DBVT$EVAX$FOCL$NCNA$NOK$SLN
International

US Equity Markets End Lower After Government Bond Yields Rise, Fed's Policy Statement

US equity indexes were lower on Wednesday as government bond yields rose and the Federal Reserve announcement excluded any language hinting at near-term rate cuts.* "Economic activity is expanding at a solid pace despite elevated uncertainty that owes, in part, to the conflict in the Middle East," the Fed statement said. "Job gains have kept pace with the workforce, and the unemployment rate has changed little."* Iran accused Israel of violating the truce in Lebanon 84 times since it reached the interim agreement with the US and warned of a "harsh response" if attacks continue, Al Jazeera reported.* July West Texas Intermediate crude oil fell $0.10 to settle at $75.95 per barrel, while August Brent crude, the global benchmark, was last seen down $0.08 at $78.87.* Moderna (MRNA) plans to invest in production sites in Germany and is interested in the plants that BioNTech (BNTX) has slated for closure, according to a Google translation of a Wednesday report from German news outlet Handelsblatt. Moderna shares were up roughly 12%, the top gainer on the S&P 500, and BioNTech stock was up about 2.9%.* Carvana (CVNA) shares were down nearly 10%, the worst performer on the S&P 500, after competitor CarMax's (KMX) fiscal Q1 earnings fell year over year on Wednesday as comparable used vehicle sales swung negative and its management flagged higher margin pressure in the near term.

Dow JonesNasdaq CompositeS&P 500$BNTX$CVNA$KMX$MRNA
Sectors

Sector Update: Healthcare Stocks Retreat Late Afternoon

Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index falling 1.3% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 1.8%.The iShares Biotechnology ETF (IBB) rose 0.7%.In corporate news, ResMed (RMD) shares fell 4.5% after Morgan Stanley downgraded the company to equalweight from overweight and cut its price target to $230 from $286.UniQure (QURE) shares surged 76% after the company said that it intends to submit a Biologics License Application for the accelerated approval of AMT-130 to treat Huntington's disease in Q3.Novo Nordisk (NVO) said it is aware of claims by cyber extortion group FulcrumSec that it stole company data and sought a $25 million payment, Reuters reported. Novo shares were up 0.2%.Moderna (MRNA) plans to invest in production sites in Germany and is interested in the plants that BioNTech (BNTX) has slated for closure, according to a Google translation of a Wednesday report from German news outlet Handelsblatt. Moderna shares jumped almost 11%, and BioNTech was up 2.3%.

$BNTX$MRNA$NVO$QURE$RMD
Wire

Sector Update: Healthcare Stocks Decline Wednesday Afternoon

Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index decreasing 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) rose 2.2%.In corporate news, IQVIA (IQV) shares fell 3.3% after Morgan Stanley downgraded the company to equalweight from overweight and cut its price target to $200 from $225.Novo Nordisk (NVO) said it is aware of claims by cyber extortion group FulcrumSec that it stole company data and sought a $25 million payment, Reuters reported. Novo shares were up 1.8%.Moderna (MRNA) plans to invest in production sites in Germany and is interested in the plants that BioNTech (BNTX) has slated for closure, according to a Google translation of a Wednesday report from German news outlet Handelsblatt. Moderna shares jumped past 8%, and BioNTech was up 4%.

$BNTX$IQV$MRNA$NVO
Asia Markets

European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

European equities traded in the US as American depositary receipts were sharply higher late Wednesday morning, rising 1.28% to 1,926.15 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by lenders Banco Santander (SAN) and Banco Bilbao Vizcaya Argentaria (BBVA), which advanced 2.5% and 2.3% respectively. They were followed by biopharmaceutical firm argenx (ARGX) and biotech firm BioNTech (BNTX), which rose 2.1% and 2% respectively.The decliners from continental Europe were led by pharmaceutical company Sanofi (SNY) and telecommunications company Nokia (NOK), which dropped 2% and 1.4% respectively. They were followed by software firm SAP (SAP) and telecommunications company Ericsson (ERIC), which were off 1% and 0.8% respectively.The gainers from the UK were led by Mereo BioPharma Group (MREO) and lender Barclays (BCS), which rose 9% and 3.6% respectively. They were followed by Akari Therapeutics (AKTX) and Bicycle Therapeutics (BCYC), which advanced 3.3% and 2.7% respectively.The decliners from the UK and Ireland were led by British American Tobacco (BTI) and telecommunications operator Vodafone Group (VOD), which fell 8% and 1.3% respectively. They were followed by oil and gas companies BP (BP) and Shell (SHEL), which were down 1.1% and 1% respectively.

$AKTX$ARGX$BBVA$BCS$BCYC$BNTX$BP$BTI$ERIC$MREO$NOK$SAN$SAP$SHEL$SNY$VOD
Asia Markets

European Equities Traded in US as ADRs Rise in Thursday Trading

European equities traded in the US as American depositary receipts rose late Thursday morning with the S&P Europe Select ADR Index climbing 1.7% to 1,874.97.From continental Europe, the gainers were led by biopharmaceutical company argenx (ARGX) and semiconductor company Sequans Communications (SQNS), which rose 2.7% and 2.6%, respectively. They were followed by biotech firm BioNTech (BNTX) and telecommunications company Nokia (NOK), which were up 2.5% and 1.6%, respectively.The decliners from continental Europe were led by software firm SAP (SAP) and internet ad firm Criteo (CRTO), which dropped 4.1% and 0.9%, respectively. They were followed by biotech firm Evaxion (EVAX) and consumer goods company Unilever (UL), which were off 0.4% and 0.1%, respectively.The gainers from the UK were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which climbed 8.8% and 4%, respectively. They were followed by lender HSBC (HSBC) and biotech firm Autolus Therapeutics (AUTL), which advanced 2.8% and 2.7%, respectively.The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and software company Endava (DAVA), which fell 4.6% and 1.1%, respectively. They were followed by biopharmaceutical companies Mereo BioPharma Group (MREO) and NuCana (NCNA), which lost 0.9% and 0.8%, respectively.

$ARGX$AUTL$BDRX$BNTX$CRTO$DAVA$EVAX$HSBC$MREO$NCNA$NOK$SAP$SLN$SQNS$TRIB$UL
Sectors

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index increasing 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.8%.The iShares Biotechnology ETF (IBB) advanced 1.7%.In corporate news, Medtronic (MDT) reported better-than-expected fiscal Q4 results on Wednesday, while the medical-device maker projected earnings and organic revenue growth for the current year. Its shares gained 5.8%.BioNTech (BNTX) cautioned that proposed healthcare reforms in Germany, due for a vote this summer, may put future investments in the country at risk, Bloomberg reported, citing Chief Commercial Officer Annemarie Hanekamp. BioNTech shares fell 0.8%.TG Therapeutics (TGTX) said its subcutaneous formulation of ublituximab showed "positive" results from a phase 1 trial comparing the multiple sclerosis therapy to the drug's intravenous version. Shares jumped past 10%.Maia Biotechnology (MAIA) shares rose 4.4% after the firm said Wednesday it has received clearance from the US Food and Drug Administration to open enrollment for the expansion of a phase 2 trial of ateganosine for advanced non-small cell lung cancer.

$BNTX$MAIA$MDT$TGTX
Sectors

Sector Update: Healthcare

Healthcare stocks rose Wednesday afternoon with the NYSE Healthcare Index increasing 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1%.The iShares Biotechnology ETF (IBB) advanced 1.7%.In corporate news, BioNTech (BNTX) cautioned that proposed healthcare reforms in Germany, due for a vote this summer, may put future investments in the country at risk, Bloomberg reported, citing Chief Commercial Officer Annemarie Hanekamp. BioNTech shares fell 1%.

$BNTX
Wire

Market Chatter: BioNTech Says Germany's Health Reforms Could Impact Investment Plans

BioNTech (BNTX) cautioned that proposed healthcare reforms in Germany, due for a vote this summer, could put future investments in the country at risk, Bloomberg reported Wednesday, citing Chief Commercial Officer Annemarie Hanekamp.Hanekamp said future investments in Germany will depend on whether policymakers can establish a stable and predictable framework for pharmaceutical companies, according to the report.The proposals, which aim to lower drug prices to curb healthcare costs, could also have implications for the US, the report added.BioNTech did not immediately respond to a request for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $88.31, Change: $-0.83, Percent Change: -0.93%

$BNTX
Asia Markets

European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading

European equities traded in the US as American depositary receipts started the trading week lower late Monday morning, declining 0.2% to 1,867.7 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by software firm SAP (SAP) and petroleum refiner Equinor (EQNR), which advanced 7.2% and 5.6% respectively. They were followed by accommodations booking site trivago (TRVG) and telecommunications company Nokia (NOK), which increased 5.2% and 4.8% respectively.The decliners from continental Europe were led by semiconductor company Sequans Communications (SQNS) and biotech firm Evaxion (EVAX), which dropped 7.2% and 4.8% respectively. They were followed by biotech firm BioNTech (BNTX) and lender Banco Bilbao Vizcaya Argentaria (BBVA), which fell 4.3% and 2.5% respectively.The gainers from the UK were led by software company Endava (DAVA) and oil and gas company BP (BP), which rose 5.9% and 3.6% respectively. They were followed by oil and gas company Shell (SHEL) and communications company WPP (WPP), which were up 2.2% and 0.9% respectively.The decliners from the UK and Ireland were led by biopharmaceutical companies Akari Therapeutics (AKTX) and Mereo BioPharma Group (MREO), which lost 13.4% and 9.5% respectively. They were followed by biopharmaceutical company NuCana (NCNA) and pharmaceutical company Silence Therapeutics (SLN), which were down 7.7% and 4.4% respectively.

$AKTX$BBVA$BNTX$BP$DAVA$EQNR$EVAX$MREO$NCNA$NOK$SAP$SHEL$SLN$SQNS$TRVG$WPP
Asia Markets

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Flat for Week

European equities traded in the US as American depositary receipts were rising late Friday morning, up 0.61% to 1,880.61 on the S&P Europe Select ADR Index, which is nearly flat for the week so far.From continental Europe, the gainers were led by medical device maker EDAP TMS (EDAP) and biotech firm BioNTech (BNTX), which rose 4.3% and 3% respectively. They were followed by software company SAP (SAP) and internet advertising firm Criteo (CRTO), which were up 2% and 0.4% respectively.The decliners from continental Europe were led by pharmaceutical company Ascendis Pharma (ASND) and telecommunications company Nokia (NOK), which fell 7.3% and 3% respectively. They were followed by accommodations booking site trivago (TRVG) and biopharmaceutical company Cellectis (CLLS), which were off 0.9% and 0.8% respectively.The gainers from the UK were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and communications company WPP (WPP), which advanced 2.4% and 1.1% respectively. They were followed by lenders Barclays (BCS) and HSBC (HSBC), which increased 1% and 0.9% respectively.The decliners from the UK and Ireland were led by biopharmaceutical companies Mereo BioPharma Group (MREO) and NuCana (NCNA), which dropped 6.6% and 4.4% respectively. They were followed by pharmaceutical company Silence Therapeutics (SLN) and tobacco company British American Tobacco (BTI), which lost 3.5% and 1.8% respectively.

$ASND$BCS$BDRX$BNTX$BTI$CLLS$CRTO$EDAP$HSBC$MREO$NCNA$NOK$SAP$SLN$TRVG$WPP
Asia Markets

European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday

European equities traded in the US as American depositary receipts were trending slightly lower late Thursday morning, declining 0.1% to 1,873.2 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by internet advertising firm Criteo (CRTO) and medical device maker EDAP TMS (EDAP), which rose 3.3% and 3.2% respectively. They were followed by biopharmaceutical company Cellectis (CLLS) and software firm SAP (SAP), which were up 2.8% and 1.2% respectively.The decliners from continental Europe were led by telecommunications company Nokia (NOK) and brewing company Anheuser-Busch InBev (BUD), which fell 2.5% and 1.4% respectively. They were followed by biopharmaceutical company Grifols (GRFS) and biotech firm BioNTech (BNTX), which were down 1.1% and 0.3% respectively.The gainers from the UK were led by biopharmaceutical company Akari Therapeutics (AKTX) and biotech firm Autolus Therapeutics (AUTL), which advanced 43.9% and 1.5% respectively. They were followed by communications company WPP (WPP) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which increased 0.9% and 0.3% respectively.The decliners from the UK and Ireland were led by pharmaceutical company Silence Therapeutics (SLN) and insurance company Prudential (PUK), which dropped 4.2% and 2.3% respectively. They were followed by lender HSBC (HSBC) and biopharmaceutical company Amarin (AMRN), which lost 2% and 0.6% respectively.

$AKTX$AMRN$AUTL$BDRX$BNTX$BUD$CLLS$CRTO$EDAP$GRFS$HSBC$NOK$PUK$SAP$SLN$WPP
Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks rose late Wednesday afternoon with the NYSE Healthcare Index gaining 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.3%.The iShares Biotechnology ETF (IBB) added 0.5%.In corporate news, BioNTech's (BNTX) cancer-drug pipeline is showing stronger early results and is approaching several important clinical milestones, improving confidence in the company's long-term outlook, UBS Securities said. BioNTech shares rose 1.4%.Corcept Therapeutics (CORT) shares jumped 9.7% after the company said it will resubmit its new drug application to the US Food and Drug Administration in the coming weeks for relacorilant to treat Cushing's syndrome.Boston Scientific (BSX) shares slumped 12% after CEO Mike Mahoney said this year has been "a bit more of a challenge" than anticipated.Guardant Health (GH) shares gained 5.6% after the company said its Shield blood test has been included in the American Cancer Society's updated Colorectal Cancer Screening guidelines.

$BNTX$BSX$CORT$GH
Sectors

Sector Update: Healthcare

Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index up 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.2%.The iShares Biotechnology ETF (IBB) added 0.6%.In corporate news, BioNTech's (BNTX) cancer-drug pipeline is showing stronger early results and is approaching several important clinical milestones, improving confidence in the company's long-term outlook, UBS Securities said in a report. UBS upgraded its rating on BioNTech stock to buy from neutral and raised its price target to $135 from $117. BioNTech shares rose 1.2%.

$BNTX
Wire

BioNTech's Cancer Pipeline Seen Strengthening Ahead of Key Trial Results, UBS Says

BioNTech's (BNTX) cancer-drug pipeline is showing stronger early results and is approaching several important clinical milestones, improving confidence in the company's long-term outlook, UBS Securities said Wednesday in a report.BioNTech is developing a new type of cancer medicine designed to both activate the immune system and cut off a tumor's blood supply, and early data from the company's lead program, pumitamig, in lung cancer have been encouraging in studies conducted in China and globally, with safety results that appear manageable, the report said.BioNTech's broader cancer pipeline remains under-recognized, and pumitamig may become competitive in several difficult-to-treat cancers, including triple-negative breast cancer and colorectal cancer, the report said. Global trial results look similar to early data from China, easing investor concerns that the treatment might not work the same way across regions, UBS said.A key moment for the field will come at the upcoming American Society of Clinical Oncology meeting, where Akeso and Summit Therapeutics (SMMT) will present overall survival data from their HARMONi-6 study, the report said. Strong results would help validate the drug approach BioNTech is pursuing and may shift sentiment around the company's oncology strategy, UBS said.UBS upgraded its rating on BioNTech stock to buy from neutral and raised its price target to $135 from $117.Price: $93.33, Change: $+1.08, Percent Change: +1.17%

$BNTX$SMMT
Asia Markets

European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading

European equities traded in the US as American depositary receipts were tracking lower late Wednesday morning, declining 0.48% to 1,880.02 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by internet advertising firm Criteo (CRTO) and biopharmaceutical company argenx (ARGX), which rose 5% and 2.8% respectively. They were followed by consumer goods company Unilever (UL) and biotech firm BioNTech (BNTX), which were up 2.1% and 1.9% respectively.The decliners from continental Europe were led by telecommunications companies Ericsson (ERIC) and Nokia (NOK), which dropped 4.1% and 3.4% respectively. They were followed by semiconductor company Sequans Communications (SQNS) and oil and gas company Eni (E), which lost 3.3% and 3% respectively.The gainers from the UK were led by biotech firm Autolus Therapeutics (AUTL) and software company Endava (DAVA), which advanced 3.7% and 3.4% respectively. They were followed by pharmaceutical company Silence Therapeutics (SLN) and alcoholic beverage company Diageo (DEO), which increased 3% and 2.7% respectively.The decliners from the UK and Ireland were led by biopharmaceutical company Akari Therapeutics (AKTX) and oil and gas company BP (BP), which fell 13% and 3.2% respectively. They were followed by utilities company National Grid (NGG) and oil and gas company Shell (SHEL), which were down 2.2% and 2.1% respectively.

$AKTX$ARGX$AUTL$BNTX$BP$CRTO$DAVA$DEO$E$ERIC$NGG$NOK$SHEL$SLN$SQNS$UL
Research

UBS Upgrades BioNTech to Buy From Neutral, Adjusts Price Target to $135 From $117

BioNTech (BNTX) has an average rating of overweight and mean price target of $125.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$BNTX
Asia Markets

European Equities Traded in the US as American Depositary Receipts Open Week Tracking Higher in Monday Trading

European equities traded in the US as American depositary receipts were heading higher late Monday morning, rising 0.88% to 1,825.10 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech firm Evaxion (EVAX) and healthcare tech company Royal Philips (PHG), which rose 4.6% and 2.9% respectively. They were followed by internet advertising firm Criteo (CRTO) and biopharmaceutical company Grifols (GRFS), which were up 2.8% each.The decliners from continental Europe were led by biopharmaceutical company DBV Technologies (DBVT) and biotech firm BioNTech (BNTX), which dropped 3.2% and 2% respectively. They were followed by telecommunications company Nokia (NOK) and pharmaceutical company Ascendis Pharma (ASND), which were down 1.9% and 0.9% respectively.The gainers from the UK were led by biotech companies Autolus Therapeutics (AUTL) and Trinity Biotech (TRIB), which climbed 16% and 6.2% respectively. They were followed by communications company WPP (WPP) and educational publisher Pearson (PSO), which advanced 4.8% and 4.7% respectively.The decliners from the UK and Ireland were led by biopharmaceutical companies NuCana (NCNA) and Biodexa Pharmaceuticals (BDRX), which fell 8.3% and 3% respectively. They were followed by biopharmaceutical companies Amarin (AMRN) and Mereo BioPharma Group (MREO), which were off 2.1% and 1% respectively.

$AMRN$ASND$AUTL$BDRX$BNTX$CRTO$DBVT$EVAX$GRFS$MREO$NCNA$NOK$PHG$PSO$TRIB$WPP

Showing 1-20 of 29

Track with the FINWIRES app suite

FolioX
FolioX
Track BNTX in your portfolio
WheelAI
WheelAI
Analyze BNTX options with the wheel strategy
StockInsider
StockInsider
See market sentiment on BNTX